Peter Barrett - 10 May 2022 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Reporting relationship: Director
Issuer ticker: LRMR
Reported as of: 10 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 May 2022, 20:27:47 UTC
Prior SEC filing: 09 May 2022
Next SEC filing: 13 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Johansson, Attorney-in-fact

Key filing fact

Peter Barrett filed Form 4 for Larimar Therapeutics, Inc. (LRMR) on 12 May 2022.

Key facts

This page summarizes Peter Barrett's Form 4 filing for Larimar Therapeutics, Inc. (LRMR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 May 2022, 20:27.

Change

Previous filing in this sequence was filed on 09 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LRMR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +8,300
Change %
Price: $0.000000
Shares after: 8,300
Date: 10 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,300
Exercise price: $2.92
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.